The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity

References

• Federation ID. IDF diabetes atlas. Brussels: International Diabetes Federation; 2013.
   Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012;379:2291–2299.
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diab Res Clin Pract. 2014;105:141–150.
   PubMed Web of Science ®Google Scholar
• Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004;79:537–543.
   PubMed Web of Science ®Google Scholar
• Tappy L, Lê K-A. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clin Res Hepatol Gastrol. 2012;36:554–560.
   PubMed Web of Science ®Google Scholar
• Bray G. Fructose: should we worry? Int J Obes. 2008;32:S127.
   Web of Science ®Google Scholar
• Kikuchi S, Shinpo K, Takeuchi M, et al. Glycation-a sweet tempter for neuronal death. Brain Res Brain Res Rev. 2003;41:306–323.
   PubMed Web of Science ®Google Scholar
• Wolozin B, Behl C. Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch Neurol. 2000;57:793–796.
   PubMed Web of Science ®Google Scholar
• Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev. 2007;56:384–402.
   PubMedGoogle Scholar
• de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2:1101–1113.
   PubMedGoogle Scholar
• Bomba M, Ciavardelli D, Silvestri E, et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis. 2013;4:e612.
   PubMed Web of Science ®Google Scholar
• Foltynie T, Aviles-Olmos I. Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic. Alzheimers Dement. 2014;10:S38–S46.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Powell AM, Kaidanovich-Beilin O, et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 2013;237:164–171.
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013;123:2730–2726.
   PubMed Web of Science ®Google Scholar
• Green B, Gault V, Flatt P, et al. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys. 2004;428:136–143.
   PubMed Web of Science ®Google Scholar
• Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol. 2012;166:27–41.
   PubMed Web of Science ®Google Scholar
• Duarte A, Candeias E, Correia S, et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. BBA Mol Basis Dis. 2013;1832:527–541.
   PubMed Web of Science ®Google Scholar
• Gault VA, Hölscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. European J Pharmacol. 2008;587:112–117.
   PubMed Web of Science ®Google Scholar
• Gault VA, Hölscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J Neurophysiol. 2008;99:1590–1595.
   PubMed Web of Science ®Google Scholar
• Hamilton A, Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009;20:1161–1166.
   PubMed Web of Science ®Google Scholar
• Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221:T31–T41.
   PubMed Web of Science ®Google Scholar
• Kovalevich J, Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013;1078:9–21.
   PubMedGoogle Scholar
• Khalilnezhad A, Erbas O, Taskiran D. The investigation of the protective effect of glucagon-like peptide (GLP-1) analogue exenatide on glucose and fructose-induced neurotoxicity. Poster presentation 42nd National Physiology Congress, 2016 September 5-8; Duzce, Turkey. Acta Physiol (Oxf). 2016;218:68.
   PubMed Web of Science ®Google Scholar
• Taskiran D, Evren V. Estradiol protects adipose tissue–derived stem cells against H2O2‐induced toxicity. J Biochem Mol Toxicol. 2012;26:301–307.
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–1625.
   PubMed Web of Science ®Google Scholar
• Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9:36.
   PubMed Web of Science ®Google Scholar
• Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006;212:167–178.
   PubMed Web of Science ®Google Scholar
• Costa CS, Del-Ponte B, Assunção MCF, et al. Consumption of ultra-processed foods and body fat during childhood and adolescence: a systematic review. Public Health Nutr. 2018;21:148–159.
   PubMed Web of Science ®Google Scholar
• Calvo-Ochoa E, Hernández-Ortega K, Ferrera P, et al. Short-term high-fat-and-fructose feeding produces insulin signaling alterations accompanied by neurite and synaptic reduction and astroglial activation in the rat hippocampus. J Cereb Blood Flow Metab. 2014;34:1001–1008.
   PubMed Web of Science ®Google Scholar
• Cisternas P, Salazar P, Serrano FG, et al. Fructose consumption reduces hippocampal synaptic plasticity underlying cognitive performance. BBA Mol Basis Dis. 2015;1852:2379–2390.
   PubMed Web of Science ®Google Scholar
• Jiménez-Maldonado A, Ying Z, Byun HR, et al. Short-term fructose ingestion affects the brain independently from establishment of metabolic syndrome. BBA Mol Basis Dis. 2018;1864:24–33.
   PubMed Web of Science ®Google Scholar
• Semchyshyn HM, Miedzobrodzki J, Bayliak MM, et al. Fructose compared with glucose is more a potent glycoxidation agent in vitro, but not under carbohydrate-induced stress in vivo: potential role of antioxidant and antiglycation enzymes. Carbohydr Res. 2014;384:61–69.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang H, Gu W, et al. Effects of exposure to high glucose on primary cultured hippocampal neurons: involvement of intracellular ROS accumulation. Neurol Sci. 2014;35:831–837.
   PubMed Web of Science ®Google Scholar
• Sharifi AM, Eslami H, Larijani B, et al. Involvement of caspase-8, -9, and -3 in high glucose-induced apoptosis in PC12 cells . Neurosci Lett. 2009;459:47–51.
   PubMed Web of Science ®Google Scholar
• Leal EC, Aveleira CA, Castilho AF, et al. High glucose and oxidative/nitrosative stress conditions induce apoptosis in retinal endothelial cells by a caspase-independent pathway. Exp Eye Res. 2009;88:983–991.
   PubMed Web of Science ®Google Scholar
• McPherson JD, Shilton BH, Walton DJ. Role of fructose in glycation and cross-linking of proteins. Biochemistry. 1988;27:1901–1907.
   PubMed Web of Science ®Google Scholar
• Münch G, Westcott B, Menini T, et al. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. 2012;42:1221–1236.
   PubMed Web of Science ®Google Scholar
• Pazdro R, Burgess JR. Differential effects of α-tocopherol and N-acetyl-cysteine on advanced glycation end product-induced oxidative damage and neurite degeneration in SH-SY5Y cells. BBA Mol Basis Dis. 2012;1822:550–556.
   PubMed Web of Science ®Google Scholar
• Bassil F, Fernagut P-O, Bezard E, et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol. 2014;118:1–18.
   PubMed Web of Science ®Google Scholar
• Spielman LJ, Gibson DL, Klegeris A. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. Eur J Cell Biol.. 2017;96:240–253.
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res. 2008;86:326–338.
   PubMed Web of Science ®Google Scholar
• Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Nation Acad Sci. 2009;106:1285–1290.
   PubMed Web of Science ®Google Scholar
• Chen S, Yin L, Xu Z, et al. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis. Neurosci Lett. 2016;612:193–198.
   PubMed Web of Science ®Google Scholar
• Li Q, Lin Y, Wang S, et al. GLP-1 Inhibits high-glucose-induced oxidative injury of vascular endothelial cells. Sci Rep. 2017;7:8008.
   PubMed Web of Science ®Google Scholar